Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-37. (Canceled).

38. (Previously Presented) A method as in claim 54, wherein methylprednisolone is released from the prosthesis at a rate between 5 µg/day to 200 µg/day.

39. (Previously Presented) A method as in claim 38, wherein methylprednisolone is released at a rate between 10 µg/day to 60 µg/day.

40. (Previously Presented) A method as in claim 54, wherein methylprednisolone is released from the prosthesis within a time period of 1 day to 45 days in a vascular environment.

41. (Previously presented) A method as in claim 40, wherein methylprednisolone is released within a time period of 7 days to 21 days in a vascular environment.

42. (Currently Amended) A method as in claim 55, wherein methylprednisolone and mizoribine are released ~~further comprising releasing the at least one other substance~~ simultaneously ~~with methylprednisolone from the prosthesis~~.

43. (Currently Amended) A method as in claim 55, wherein methylprednisolone and mizoribine are released ~~further comprising releasing the at least one other substance~~ sequentially ~~with methylprednisolone from the prosthesis~~.

44. (Canceled).

45. (Previously Presented) A method as in claim 54, wherein the releasing comprises delaying substantial release of methylprednisolone for at least one hour following implantation of the prosthesis.

46. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone from a reservoir with a material that at least partially degrades in a vascular environment over said one hour.

47. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone with a matrix that at least partially degrades in a vascular environment over said one hour.

48. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone with a nondegradable matrix that allows diffusion of methylprednisolone through the nondegradable matrix after said one hour.

49. (Previously Presented) A method as in claim 45, wherein delaying release comprises slowing releasing methylprednisolone with a rate limiting barrier that allows diffusion of methylprednisolone through the barrier after said one hour.

50. (Original) A method as in any one of claims 47-49, wherein the prosthesis is coated with the matrix or barrier by spraying, dipping, deposition, or painting.

51.-53. (Canceled).

54. (Previously Presented) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:

implanting a vascular prosthesis in the blood vessel; and

releasing methylprednisolone and mycophenolic acid from the prosthesis when implanted in the blood vessel.

55. (Currently Amended) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:

implanting a vascular prosthesis in the blood vessel; and

releasing methylprednisolone and mizoribine ~~at least one other substance in addition to methylprednisolone~~ from the prosthesis when implanted in the blood vessel~~, wherein the at least one other substance comprises mizoribine~~.

56. (Previously Presented) A method as in claim 54, wherein methylprednisolone is substantially released within a time period of 2 days to 3 months.

57. (Canceled).

58. (Previously Presented) A method as in claim 54, wherein methylprednisolone and mycophenolic acid are released simultaneously.

59. (Previously Presented) A method as in claim 54, wherein methylprednisolone and mycophenolic acid are released sequentially.

60.-61. (Canceled)

62. (Previously Presented) A method as in claim 55, wherein methylprednisolone is released from the prosthesis at a rate between 5 μg/day to 200 μg/day.

63. (Previously Presented) A method as in claim 62, wherein methylprednisolone is released at a rate between 10 μg/day to 60 μg/day.

64. (Previously Presented) A method as in claim 55, wherein methylprednisolone is released from the prosthesis within a time period of 1 day to 45 days in a vascular environment.

65. (Previously Presented) A method as in claim 64 , wherein methylprednisolone is released within a time period of 7 days to 21 days in a vascular environment.

66. (Previously Presented) A method as in claim 55, wherein the releasing comprises delaying substantial release of methylprednisolone for at least one hour following implantation of the prosthesis.

67. (Previously Presented) A method as in claim 66 , wherein delaying release comprises slowing releasing methylprednisolone from a reservoir with a material that at least partially degrades in a vascular environment over said one hour.

68. (Previously Presented) A method as in claim 66, wherein delaying release comprises slowing releasing methylprednisolone with a matrix that at least partially degrades in a vascular environment over said one hour.

69. (Previously Presented) A method as in claim 66, wherein delaying release comprises slowing releasing methylprednisolone with a nondegradable matrix that allows diffusion of methylprednisolone through the nondegradable matrix after said one hour.

70. (Previously Presented) A method as in claim 66, wherein delaying release comprises slowing releasing methylprednisolone with a rate limiting barrier that allows diffusion of methylprednisolone through the barrier after said one hour.

71. (Previously Presented) A method as in any one of claims 68-70, wherein the prosthesis is coated with the matrix or barrier by spraying, dipping, deposition, or painting.

72. (Previously Presented) A method as in claim 55, wherein methylprednisolone is substantially released within a time period of 2 days to 3 months.